Active Research

Divison	Study Area	Principal Investigator (PI)	Contact Infromation	Study Name and Type	Study Description	Main Incusion Criteria	Recruiting	Open
Celiac Disease	Celiac	David Elliott, MD, PhD david-elliott@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	KAN-101, synthetic liver-targeting glycopolymer that is conjugated to a synthetic immunodominant peptide domain of wheat alpha gliadin	A Phase 1B open-label/ phase 2 Double-blind, Placebo controlled study for pharmacodynamic activity, pharmacokinetics, safety and tolerability of KAN-101 in patients with celiac disease	Celiac disease with positive serology and intestinal histology with HLA-DQ2.5 genotype	Yes	Yes
Inflammatory Bowel	Ulcerative Colitis	Steven Polyak, MD steven-polyak@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	Abivax ABX464 – oral, anti-inflammatory drug that upregulates miR-124 and initiates anti-inflammatory effects	ABTECT-2: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis	Moderate to severe UC, history of inadequate response to, loss of response response to, loss of response to, or intolerance to at least one conventional therapy for UC	Yes	Yes
Inflammatory Bowel	Crohn's Disease	Steven Polyak, MD steven-polyak@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	Abivax ABX464 – oral, anti-inflammatory drug that upregulates miR-124 and initiates anti-inflammatory effects	ENHANCE-CD: A phase 2b, multicenter, double-blind, placebo-controlled, study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of obfazimod in subjects with moderately to severely active Crohn's disease	Moderate to severe UC, history of inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC	Yes	Yes
Inflammatory Bowel	Crohn's Disease	Steven Polyak, MD steven-polyak@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	Takeda TAK-279-CD - oral TYK2	TAK-279-CD-2001: A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn's Disease	Moderate to severe CD, history of inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD	Yes	Yes
Inflammatory Bowel	Crohn's Disease	Steven Polyak, MD steven-polyak@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	TRX Bio: TRX103-02 Cell Therapy Infusion	TRX Bio: A phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects with Merate to Severe Treatment-Refractory Crohn's Disease	Moderate to severe CD, history of inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD	Yes	Yes
Inflammatory Bowel	Crohn's Disease	Divya Ashat, MD diva-ashat@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	VOICE/TAK01796; Observational Study in patients with Crohn's Disease and Vedolizumab	Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants with Crohn's Disease Using Patient-Reported Outcome Measures (VOICE): A Prospective Obervational Study	Patient with confirmed CD and prescribed Vedolizumab	Yes	Yes
Inflammatory Bowel		Steven Polyak, MD steven-polyak@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu		Dr. Polyak is open to defining and starting up any clinical IBD research project if there are interested residents or students. This requires more time when starting up.		Yes	Yes
Liver	Alpha 1 Antitrypsin Deficiency	Tomohiro Tanaka, MD tomohiro-tanaka@uiowa.edu	Julie Szewc, RN, BSN (319) 467-4923 julie-szewc@uiowa.edu	Takeda TAK-999-3001 ~SC Injextion RNAi therapeutic	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Faziesiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F$ Fibrosis	Alpha-1 Antitrypsin Deficiency, PiZZ	Yes	Yes
Liver	Bio89 MASH	Antonio Sanchez, MD antonio-sanchez@uiowa.edu	Julie Szewc, RN, BSN (319) 467-4923 julie-szewc@uiowa.edu	Bio89-100-131 and Bio90-100-132	131: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfuction-Associated Steatohepatitis (MASH) and Fibrosis 132: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)	F2-F3 or F4	Yes	Yes
Liver	PBC	Alan Gunderson, MD alan-gunderson@uiowa.edu	Julie Szewc, RN, BSN (319) 467-4923 julie-szewc@uiowa.edu	CB8025-41837- oral capsule, seladelpar - peroxisome proliferator-activated receptor delta	AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clincial Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis	PBC and compensated cirrhosis	Yes	Yes
Liver	PBC	Antonio Sanchez, MD antonio-sanchez@uiowa.edu	Jena Neuhaus, RN, BSN (319) 335-0123 jena-neuhaus@uiowa.edu	Mirum PBC Clinical Trial – Oral Volixibat	Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)	PBC	Yes	Yes
Liver	NAFLD	Frederick Johlin, MD frederick-johlin@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	NAFLD Treatment with SIRT1 Oral Therapy	Investigation of the Effect of Antioxidant Therapy and SIRT1 Stimulation in Patients with Non-Alcoholic Fatty Liver Disease from Metabolic Syndrome	NAFLD, F2 or F3	Yes	Yes
Motility	Eosinophilic Esophagitis (EoE)	Rami El Abiad, MD rami-elabiad@uiowa.edu	Ethan Hoover, RN (319) 335-9767 ethan-hoover@uiowa.edu	AstraZeneca Crossing EoE (Tezepelumab) – SC mAb IgG2λ	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)	Biopsy proven EoE, experiencing dysphagia symptoms	Yes	Yes
Motility	Eosinophilic Esophagitis (EoE)	Rami El Abiad, MD rami-elabiad@uiowa.edu	Ethan Hoover, RN (319) 335-9767 ethan-hoover@uiowa.edu	Uniquity One - SC Ig G1 monoclonal antibody that binds to human TSLP	A Phase 2, Randomized, Double-Blind, Multicenter Placebo-Controlled Study with an Open-Label Extension to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinphilic Esophagitis (ALAMERE)	Biopsy proven EoE, experiencing dysphagia symptoms	Yes	Yes
Motility	C Diff	Divya Ashat, MD divya-ashat@uiowa.edu	Megan Sharer, RN, BSN, MBA (319) 467-4769 megan-sharer@uiowa.edu	Ferring ROAR Rebyota Prospective Registry	REBYOTA for the Prevention of Recurrence of Closridioides Difficile Infection (CDI) in Adult Patients: An Observational Study	Patients with C Diff receiving Rebyota	Yes	Yes